WarpBuild introduces Helios, the AI-native workflow automation and collaboration product for engineering teams ...
Natixis Advisors LLC acquired a new stake in Helios Technologies, Inc. (NASDAQ:HLIO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund ...
Appointment of Chief Executive Officer and PDMR Notification LONDON, UNITED KINGDOM / ACCESS Newswire / March 24, 2025 / Argo Blockchain plc, ...
Users love its chic design and its ability to maintain the health of curly hair while enhancing its natural beauty. Its ...
Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...
Dine out for a cause Monday ...
Otsego County Office for the Aging will once again host a five-week presentation series titled “Planning for Successful Aging ...
This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
Welcome back to TechCrunch Mobility — your central hub for news and insights on the future of transportation. Sign up here ...
Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...
Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback